+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing how long adults with moderate to severe active rheumatoid arthritis RA continue treatment with Upadacitinib UPA versus tumor necrosis factor inhibitors TNFi under real-world conditions in Germany. This observational study includes about 678 participants across approximately 80 sites and aims to understand treatment persistence over time. Participants will receive either Upadacitinib or a TNFi as prescribed by their doctors according to local labels and standard care practices. The choice of treatment is made independently of the study, and the study does not assign treatments but observes patients receiving these therapies in routine care. During the study, participants will be followed for up to 24 months to monitor how long they continue their prescribed treatment. Researchers will collect data on treatment retention rates and other health information during this period. The total study duration, including recruitment and follow-up, is about 48 months.

Age: 18Years +All Genders
75 locations
I

Actively Recruiting

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

Age: 18Years - 75YearsAll Genders
132 locations
E

Actively Recruiting

Researchers are collecting real-world data on advanced prostate cancer to evaluate the role of next-generation imaging NGI, such as PETCT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. This study focuses on men aged 18 or older with confirmed prostate cancer who need imaging to assess possible metastases either at diagnosis or after relapse. It aims to understand when NGI should be used, how it influences treatment decisions, and its impact on patient outcomes. Participants will receive standard care without experimental treatments. Imaging will be done using either conventional methods, NGI, or both, according to local clinical practice and guidelines. The study includes a cross-sectional observation to evaluate imaging benefits and a longitudinal observation to assess survival outcomes and treatment response based on the imaging approach used. During the study, data will be collected from medical records including patient demographics, medical history, tumor characteristics, and imaging results. Researchers will track the proportion of patients requiring each imaging type and changes in treatment prompted by imaging results within 4 to 6 weeks. The study involves no additional procedures beyond routine care, and participation will continue until the study end in December 2026.

Age: 18Years +MALE
24 locations
O

Actively Recruiting

Researchers are evaluating real-world clinical and patient-reported outcomes in adults with systemic lupus erythematosus SLE who are starting subcutaneous anifrolumab treatment for the first time. This prospective, single-arm, multicenter non-interventional study aims to describe key treatment goals such as remission DORIS and low disease activity LLDAS, quality of life, medication patterns, flares, and organ damage in routine care. Participants will be observed over a 24-month period while receiving subcutaneous anifrolumab as prescribed in routine clinical practice, following the applicable European summary of product characteristics. The study does not intervene in treatment decisions but collects information on disease activity, medication use, and clinical outcomes during this time. During the 24 months, data will be collected from routine visits including assessments of disease activity indices, patient questionnaires on fatigue and quality of life, and monitoring of flares and organ damage. Researchers will measure outcomes such as the proportion of patients achieving remission at 24 months and changes in disease activity scores, aiming to capture long-term disease control and treatment patterns.

Age: 18Years - 130YearsAll Genders
21 locations